Apnimed, Inc. (APMD)
14.46
+0.30
(+2.12%)
USD |
NASDAQ |
Nov 06, 10:23
Apnimed Enterprise Value : 742.98M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 742.98M |
| November 04, 2026 | 790.43M |
| November 03, 2026 | 780.44M |
| November 02, 2026 | 794.60M |
| October 30, 2026 | 836.23M |
| October 29, 2026 | 875.36M |
| October 28, 2026 | 950.71M |
| October 27, 2026 | 964.87M |
| October 26, 2026 | 942.39M |
| October 23, 2026 | 944.05M |
| October 22, 2026 | 924.90M |
| October 21, 2026 | 940.31M |
| October 20, 2026 | 924.07M |
| October 19, 2026 | 844.35M |
| October 16, 2026 | 892.85M |
| October 15, 2026 | 913.04M |
| October 14, 2026 | 870.78M |
| October 13, 2026 | 895.76M |
| October 12, 2026 | 929.06M |
| October 09, 2026 | 924.49M |
| October 08, 2026 | 912.00M |
| October 07, 2026 | 904.50M |
| October 06, 2026 | 929.90M |
| October 05, 2026 | 1.059B |
| October 02, 2026 | 1.049B |
| Date | Value |
|---|---|
| October 01, 2026 | 1.092B |
| September 30, 2026 | 1.066B |
| September 29, 2026 | 1.148B |
| September 28, 2026 | 1.056B |
| September 25, 2026 | 1.031B |
| September 24, 2026 | 1.054B |
| September 23, 2026 | 1.090B |
| September 22, 2026 | 1.215B |
| September 21, 2026 | 1.245B |
| September 18, 2026 | 1.361B |
| September 17, 2026 | 1.324B |
| September 16, 2026 | 1.281B |
| September 15, 2026 | 1.218B |
| September 14, 2026 | 1.217B |
| September 11, 2026 | 1.245B |
| September 10, 2026 | 1.269B |
| September 09, 2026 | 1.322B |
| September 08, 2026 | 1.352B |
| September 04, 2026 | 1.296B |
| September 03, 2026 | 1.311B |
| September 02, 2026 | 1.312B |
| September 01, 2026 | 1.271B |
| August 31, 2026 | 1.246B |
| August 28, 2026 | 1.390B |
| August 27, 2026 | 1.349B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| IGC Pharma, Inc. | 20.08M |
| Cocrystal Pharma, Inc. | 12.89M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -121.78M |
| Fulcrum Therapeutics, Inc. | -32.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 126.11M |
| Revenue (Quarterly) | 12.08M |
| Total Expenses (Quarterly) | -114.03M |
| EPS Diluted (Quarterly) | 3.025 |
| Gross Profit Margin (Quarterly) | 89.98% |
| Earnings Yield | 16.16% |
| Operating Earnings Yield | 3.96% |
| Normalized Earnings Yield | 16.38 |